Federal Circuit won’t revisit revived Illumina DNA test patents

06-08-2020

Muireann Bolger

Federal Circuit won’t revisit revived Illumina DNA test patents

The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.


Illumina, Federal Circuit, DNA, pregnancy, biotechnology, Roche, Ariosa, foetal, patents, court, ruling, en banc

LSIPR